Kinnate Biopharma, Inc., a San Diego, CA-based precision oncology company focused on the discovery and development of novel kinase inhibitors, raised $74.5M in Series B financing.
New investors OrbiMed, Nextech Invest Ltd., and Vida Ventures LLC participated in the round along with existing investors Foresite Capital and Eshelman Ventures. In conjunction with the financing, Carl Gordon, Ph.D., CFA, Managing Partner at OrbiMed, Brett Zbar, M.D., Managing Director at Foresite Capital, and Michael Rome, Ph.D., Partner at Foresite Capital, have also joined the company’s board of directors.
Proceeds from the financing will be used to advance several development candidates from the company’s existing programs into the clinic, and to fund new research programs.
Led by Stephen Kaldor, Ph.D., co-founder and CEO, and Eric Murphy, Ph.D., co-founder and CSO, Kinnate Biopharma is a precision oncology company advancing a pipeline of therapeutics to treat patients with genomically defined vulnerabilities. Its focus is on the design and development of selective small molecules with the mission to provide the right drug to the right patient.